EMA Recommends Granting a Marketing Authorisation for Gilteritinib
It is indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
Evidence for efficacy is based on the results from the TITAN trial
Simultaneous Review Decisions for Pembrolizumab Plus Lenvatinib in Australia, Canada and US
Combination treatment concerns patients with advanced endometrial carcinoma who progressed on prior systemic treatment and whose tumours are not MSI-H or dMMR
EMA Recommends Refusal of the Marketing Authorisation for Doxolipad
Doxolipad, a hybrid medicine, contains the active substance doxorubicin
Horizon Europe 2021-2027
The next research and innovation framework programme
In High- and Some Middle-Income Countries, Deaths From Cancer Are Now More Common Than Those From Cardiovascular Disease
PURE findings reflect transition in the predominant causes of deaths in middle-age
EMA Reviews Data on Skin Cancer With Ingenol Mebutate
The review was triggered by data from several studies showing a higher number of skin cancer cases in patients using a gel for treating actinic keratosis
Treatment of Gynaecologic Malignancies During Pregnancy
Third international consensus meeting-based guidelines
Menopausal Hormone Therapy Starting at Age 50 Years Increases Breast Cancer Incidence in Women of Average Weight in Developed Countries
Findings from an individual participant meta-analysis of the worldwide epidemiological evidence
Increased Risk for Cardiovascular Diseases in Survivors of Adult Cancers
Strategies to minimise and manage cardiovascular risk are needed for the growing population of cancer survivors
EMA/FDA Analysis Shows High Degree of Alignment in Marketing Application Decisions Between EU and US
The study also looked at applications for which the two agencies had different outcomes
A Subset of Patients Develops Off-Target Mechanisms of Resistance to TRK Inhibition
Resistance mediated by genomic alterations implicated in the MAPK pathway described